Patents by Inventor Christopher Richard Diorio

Christopher Richard Diorio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20200121673
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 23, 2020
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Oral formulations and lipophilic salts of methylnaltrexone
    Patent number: 10507206
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: December 17, 2019
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20190314365
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 17, 2019
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Oral formulations and lipophilic salts of methylnaltrexone
    Patent number: 10376505
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 13, 2019
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Oral formulations and lipophilic salts of methylnaltrexone
    Patent number: 10307417
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: June 4, 2019
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20190117646
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 25, 2019
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20190117645
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 25, 2019
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20160206612
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: March 15, 2016
    Publication date: July 21, 2016
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Oral formulations and lipophilic salts of methylnaltrexone
    Patent number: 9314461
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: April 19, 2016
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
    Patent number: 9211264
    Abstract: The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: December 15, 2015
    Assignee: WYETH LLC
    Inventors: Sripriya Venkata Ramana Rao, Syed Muzafar Shah, Christopher Richard Diorio, Maja Vencl-Joncic, Eugene Murphy
  • Oral formulations and lipophilic salts of methylnal trexone
    Patent number: 8956651
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: February 17, 2015
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20140249171
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: July 31, 2013
    Publication date: September 4, 2014
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA
    Publication number: 20140004203
    Abstract: The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicant: Wyeth LLC
    Inventors: Sripriya Venkata Ramana Rao, Syed Muzafar Shah, Christopher Richard Diorio, Maja Vencl-Joncic, Eugene Murphy
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20130330407
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Wyeth, LLC
    Inventors: Syed M. SHAH, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
    Patent number: 8524281
    Abstract: The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: September 3, 2013
    Assignee: Wyeth LLC
    Inventors: Sripriya Venkata Ramana Rao, Syed Muzafar Shah, Christopher Richard Diorio, Maja Vencl-Joncic, Eugene James Murphy
  • Oral formulations and lipophilic salts of methylnaltrexone
    Patent number: 8524276
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: September 3, 2013
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20120070495
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: March 10, 2011
    Publication date: March 22, 2012
    Applicant: WYETH LLC
    Inventors: Syed M. SHAH, Christopher Richard DIORIO, Eric C. EHRNSPERGER, Xu MENG, Kadum A. AL SHAREFFI, Jonathan Marc COHEN
  • COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA
    Publication number: 20110165257
    Abstract: The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.
    Type: Application
    Filed: November 5, 2010
    Publication date: July 7, 2011
    Applicant: Wyeth LLC
    Inventors: Sripriya Venkata Ramana Rao, Syed Muzafar Shah, Christopher Richard Diorio, Maja Vencl-Joncic, Eugene Murphy
  • O-DESMETHYLVENLAFAXINE AND BAZEDOXIFENE COMBINATION PRODUCT AND USES THEREOF
    Publication number: 20100221445
    Abstract: A combination product containing at least two active compounds, O-desmethylvenlafaxine or a pharmaceutically acceptable salt thereof and bazedoxifene or a pharmaceutically acceptable salt thereof is described. Also described are methods of making and using this combination product to treat a variety of conditions associated with low circulating estrogen levels or low estrogen receptor activity.
    Type: Application
    Filed: April 30, 2010
    Publication date: September 2, 2010
    Applicant: Wyeth LLC
    Inventors: Syed M. Shah, Mahdi B. Fawzi, Christopher Richard Diorio
  • Solid dosage formulations
    Publication number: 20070259041
    Abstract: Solid dosage formulations are provided for a compound having the formula: wherein R2 is Cl, F, Br, CH3, CF3, SCH3, NHCH3, NO2, CN, OH, OC1—C6 alkyl, or substituted OC1—C6 alkyl, or a prodrug or a pharmaceutically acceptable salt thereof. Formulations for tablets and multiparticulates containing a compound according to the above formula, a rate controlling component, and a binder are described, including formulations containing a seal coating, release rate controlling coating, and/or enteric coating. Pharmaceutical uses and kits thereof are also described.
    Type: Application
    Filed: May 3, 2007
    Publication date: November 8, 2007
    Applicant: Wyeth
    Inventors: Christopher Richard Diorio, Eric Ehrnsperger, Syed M. Shah